Adenosine deaminase-deficient severe combined immunodeficiency

Ex vivo gene addition to autologous CD34+ HSPCs has proven effective for ADA-SCID across multiple pathogenic ADA variants including c.632G>A (p.Arg211His). Strimvelis (gamma-retroviral, EMA-approved 2016) provided the first clinical validation, and lentiviral successors (OTL-101/NCT02999984) offer improved safety via self-inactivating vector design that reduces insertional oncogenesis risk.

The p.Arg211His variant (ClinVar VCV000001957, OMIM 608958.0004, dbSNP rs121908716) affects a conserved residue in the ADA catalytic domain and is classified as pathogenic by multiple submitters. Long-term follow-up of Strimvelis-treated patients published in Nature Medicine (PMID:38355973) demonstrated sustained immune reconstitution with ADA enzyme activity and T-cell recovery over 5+ years post-treatment. The lentiviral OTL-101 trial (NCT02999984, completed) showed comparable efficacy with self-inactivating vectors. A newer lentiviral trial (NCT03645460) using an improved vector is actively recruiting. The gene therapy approach is variant-agnostic — the transgene supplies functional ADA cDNA regardless of the underlying mutation.

Reduced-intensity busulfan conditioning is required, carrying gonadotoxicity and myelosuppression risk. Strimvelis long-term follow-up revealed T-cell lymphoproliferative events in a small number of gamma-retroviral-treated patients, which motivated the switch to lentiviral SIN vectors. The p.Arg211His variant retains partial enzymatic activity; some patients may present with delayed-onset or partial ADA deficiency where PEG-ADA enzyme replacement therapy (Revcovi) remains a viable alternative or bridge. Manufacturing requires specialized GMP cell-processing facilities, limiting global access particularly in regions without established transplant infrastructure.

ADA c.986C>T (p.Ala329Val) is a pathogenic missense variant in the ADA barrel domain that severely impairs enzymatic activity, leading to toxic deoxyadenosine accumulation and profound T/B/NK lymphocyte dysfunction. For this variant, pegademase bovine (Revcovi/PEG-ADA) enzyme replacement therapy is the immediate bridging strategy, but hematopoietic stem cell gene therapy (HSC-GT) with lentiviral ADA cDNA transfer represents the definitive curative option with superior long-term immune reconstitution compared to matched unrelated donor HSCT. The sequencing decision—ERT bridge followed by HSC-GT versus early HSCT—should be driven by donor availability, patient age at diagnosis, and center expertise.

Aiuti et al. (NEJM 2009, PMID:19713094) established the proof of concept for retroviral ADA-HSC-GT with durable immune reconstitution in 10 patients over 4 years. The subsequent lentiviral vector program (OTL-101, Orchard Therapeutics) showed CD4+ T-cell counts >500/μL in 90% of patients at 24 months in the Phase 2 trial (Shaw et al., NEJM 2017, PMID:28910237). PEG-ADA (Revcovi) provides metabolic detoxification within days—plasma dAXP clearance is typically >80% within 2 weeks—allowing immune reconstitution sufficient for opportunistic infection prevention during the transplant preparatory phase. Structural analysis of ADA p.Ala329Val predicts destabilization of the C-terminal barrel with reduced Zn2+ coordination geometry, consistent with the near-zero residual enzymatic activity (<1% of normal) reported in fibroblast assays for this allele.

PEG-ADA ERT does not achieve full immune reconstitution—T-cell counts plateau at subtherapeutic levels in most patients over time, and long-term ERT is associated with progressive loss of efficacy due to anti-PEG antibody development. For HSC-GT, conditioning intensity (busulfan AUC targeting) must be calibrated carefully in this immunocompromised population to avoid regimen-related toxicity while ensuring sufficient engraftment. Long-term genotoxicity data from lentiviral integration sites remain under surveillance; no insertional oncogenesis events have been reported in ADA-GT through 15+ year follow-up, but the dataset is limited. ERT must be discontinued before HSC-GT to avoid PEG-ADA competing with gene-corrected cells for proliferative advantage—the washout timing requires careful coordination.

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Adenosine deaminase-deficient severe combined immunodeficiency targeting the ADA c.632G>A (p.Arg211His) variant (Pathogenic, missense variant, non-coding transcript variant, intron variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct pathogenic ADA loss-of-function variants in autologous hematopoietic stem cells at the ADA locus to restore sufficient ADA activity, clear toxic purine metabolites, and achieve durable immune . Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: ADA NM_000022.4(ADA):c.632G>A (p.Arg211His) is classified as Pathogenic (ClinVar variation ID 1957). Molecular consequence: missense variant, non-coding transcript variant, intron variant. Protein change: R211H, R76H. 2. Epidemiology: ADA-SCID is an ultra-rare primary immunodeficiency with estimated incidence between roughly 1 in 200,000 and 1 in 1,000,000 live births. Classic disease presents in early infancy with severe, recurrent opportunistic infections, failure to thrive, and non-immune manifestations; without definitive tre 3. Standard of care: Consensus guidelines recommend initiating polyethylene glycol–modified bovine ADA enzyme replacement therapy (ERT) at diagnosis, then proceeding to definitive therapy with either allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-matched sibling/family donor or autologous hematopo 4. Pipeline: Multiple Phase I/II and Phase II trials of ex vivo ADA HSC gene therapy using gammaretroviral or lentiviral vectors have demonstrated stable multilineage engraftment, sustained ADA expression, metabolic correction, and long-term immune reconstitution, with patients remaining free from severe infecti 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting ADA c.632G>A (p.Arg211His) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.